Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...

Shares of Hims & Hers Health ( HIMS -24.30%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...

The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.

The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.

Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...

Hims & Hers Health Inc. is expanding beyond its successful foray into providing copycat weight-loss drugs with the ...

Hims & Hers Health (HIMS) stock falls as the FDA declares that Novo Nordisk's (NVO) weight loss therapies are no longer in ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 24% in the afternoon session after U.S. Food and Drug Administration (FDA) reported that the shortage of weight-loss drugs such as ...

Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...

Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...